Market Overview

Semiconductor stocks are dragging the Nasdaq lower this morning as TSMC sold off on earnings and memory names (Sandisk, SK Hynix) plunge. However, the broader market is finding some support from record bank earnings and yesterday’s cooler-than-expected PPI data (-0.3% MoM), which is fueling rate cut optimism. We’re seeing a clear rotation out of high-multiple tech into beaten-down value, consumer discretionary, and healthcare names — many of today’s top gainers sport single-digit RSIs, suggesting oversold bounces.

Claude’s Call

FLAT — The semi selloff will weigh on index-level performance, but cooling inflation and strong bank earnings provide a floor; I expect the S&P 500 to close within ±0.3% as rotation beneath the surface dominates the tape rather than directional conviction.

Top Movers

CDNA (+21.8%) — $36.52 → $42.00 (+15.0% upside) Thesis: The Naveris acquisition closes and gives CareDx a high-growth oncology vertical (HPV-driven cancer detection) on top of its transplant diagnostics franchise — this is a legitimate strategic expansion into a TAM that analysts have been waiting for. RSI at 43.6 means it’s not overheated yet, and the stock has been building a base over recent months after choppy trading. Management is clearly executing on a precision diagnostics pivot and Goldman hosted them for an investor discussion, signaling institutional interest is growing. Levels: Exit at $42 (prior 6-month high area). Support at $30 (recent consolidation floor).

MAAS (+14.2%) — $18.50 → $22.00 (+18.9% upside) Thesis: This is a China-listed ADR riding the AI infrastructure narrative — it surged 84% in April on “full-stack AI” positioning and has continued climbing. However, RSI at 38.5 suggests it’s not technically overbought despite the move, and there’s no fresh news today, making this likely momentum/retail continuation from its earlier AI re-rating. The valuation story here from May showed extreme momentum (78% in 30 days), so this could be a speculative continuation rather than fundamental. Levels: Exit at $22 (psychological round number and extension target). Support at $15.50 (prior breakout level).

SMG (+9.1%) — $73.04 → $80.00 (+9.5% upside) Thesis: This is a textbook oversold bounce — RSI at 14.14 is screaming capitulation, and the stock is rallying on maintained guidance and Stifel’s reiterated Buy rating with a $75 target. Scotts Miracle-Gro has been punished by seasonal softness in lawn/garden but the fundamental story (productivity gains, reaffirmed FY guidance) hasn’t deteriorated. When RSI is this low and the stock bounces on volume, mean reversion trades tend to have legs for 1-2 weeks. Levels: Exit at $80 (50-day MA area and Stifel’s $75 target gives conviction to hold through). Support at $67 (recent 52-week low area).

CTAS (+5.9%) — $204.09 → $225.00 (+10.2% upside) Thesis: Cintas just reported record FY26 results and issued FY27 revenue guidance of $12.1-12.25B that exceeded consensus — this is a genuine earnings beat driving re-rating. RSI at 14.9 tells you this quality compounder was deeply oversold coming into the print, so the combination of extreme technical oversold + fundamental beat is as clean a setup as you’ll find. The company posted $2B in net income and is guiding for continued mid-single-digit organic growth. Levels: Exit at $225 (pre-selloff support-turned-resistance zone). Support at $193 (yesterday’s close).

CNMD (+5.4%) — $44.29 → $50.00 (+12.9% upside) Thesis: CONMED is exploring a potential sale — this is M&A speculation driving a re-rating, and the RSI at 71.5 tells you the stock has already moved materially. Buyout rumors in medtech tend to have staying power because strategic acquirers (Stryker, Medtronic, J&J) need bolt-on deals. However, chasing M&A rumors is inherently binary. Levels: Exit at $50 (round number and likely where a deal premium would land based on prior medtech M&A multiples). Support at $40 (pre-rumor level).

BBWI (+4.6%) — $21.37 → $25.00 (+17.0% upside) Thesis: Bath & Body Works launching in Brazil provides a legitimate growth catalyst (new international TAM), and at RSI 6.46 this stock was absurdly oversold — one of the lowest RSI readings I’ve seen on a brand with this kind of consumer loyalty. The stock is down 30% over the past year but now has a fresh narrative with international expansion. Valuation articles suggest it could be 43% below fair value. Levels: Exit at $25 (pre-selloff support level and 20-day MA area). Support at $20 (round number/psychological floor).

URBN (+4.2%) — $76.07 → $85.00 (+11.7% upside) Thesis: Zacks just named Urban Outfitters “Bull of the Day” citing record-breaking results and accelerating sales growth. RSI at 6.62 is extreme capitulation territory — this stock was sold off hard during the Iran/geopolitical scare and is now snapping back. Record results + single-digit RSI is the definition of a mean-reversion trade. Levels: Exit at $85 (50-day MA area). Support at $73 (today’s open/recent low).

HOG (+4.1%) — $26.67 → $30.00 (+12.5% upside) Thesis: Harley-Davidson got downgraded to junk by S&P and booted from large-cap indexes, creating forced selling that pushed RSI to 8.72 — now the bounce is underway. The credit downgrade is real and concerning, but the stock already prices in significant distress at these levels. This is a “sell the news” exhaustion bounce, not a long-term hold. Levels: Exit at $30 (prior support-turned-resistance). Support at $25 (52-week low area).

Headlines to Watch

  • Nasdaq slides on semiconductor weakness (TSMC, SK Hynix, Sandisk) — If you own memory/foundry names, the earnings-driven reset could create buying opportunities in MU/TSM later this week once selling exhausts.
  • PPI drops 0.3% MoM, steepest decline in over a year — This strengthens the Fed rate cut case and benefits rate-sensitive sectors (REITs, homebuilders, small caps).
  • DTCC launches live tokenization pilot with BlackRock, Vanguard, JPMorgan — Crypto/digital asset infrastructure plays could see sustained interest as institutional adoption accelerates.
  • SpaceX falls back to $135 IPO price — The highest-profile IPO of 2026 losing all post-debut gains signals risk appetite for speculative growth is fading.
  • Iran ceasefire uncertainty continues — Trump’s aggressive posture on Iran remains a tail risk; oil-sensitive and consumer discretionary names get whipsawed on every headline.
  • Record bank earnings — Financials providing a backstop for the S&P; the earnings season narrative is “better than feared” so far.
  • CONMED exploring potential sale — Medtech M&A cycle continues; watch for read-throughs to other small/mid-cap surgical names.

Claude’s Top Picks

CTAS (+5.9% today, +14.9% week) — $204.09 → $225.00 (+10.2% upside) Valuation: Even after today’s pop, CTAS trades below its 5-year average forward P/E given the 9% YoY decline in shares — cheap relative to its own history for a 30+ year compounder. Upside: Record profitability + raised FY27 guidance + RSI still at 14.9 means this oversold bounce has room to mean-revert toward the 50-day MA. Risk: Broader market sell-off accelerates and drags quality names back down; macro slowdown could pressure uniform/facility services demand.

BBWI (+4.6% today, +7.2% week) — $21.37 → $25.00 (+17.0% upside) Valuation: Trading at potentially 43% below fair value per recent analysis; at a forward P/E in the low teens for a brand with 20%+ operating margins, this is cheap vs. specialty retail peers. Upside: Brazil launch adds a new growth vector, RSI at 6.5 is extreme oversold, and the stock has mean-reversion potential of 15-20% just to normalize. Risk: Consumer spending weakens further; Iran/oil headlines resume selling pressure on discretionary names.

SMG (+9.1% today, +11.9% week) — $73.04 → $80.00 (+9.5% upside) Valuation: Trading at Stifel’s $75 target already, but at an RSI of 14 with reaffirmed guidance, EV/EBITDA is likely at the bottom of its 5-year range — cheap for a category leader. Upside: Peak lawn/garden season still underway; maintained guidance removes the bear case of a cut; extreme oversold RSI suggests 1-2 more weeks of bounce. Risk: Hawthorne (cannabis) segment remains a drag; if spring sell-through data disappoints, the next update could finally trigger a guidance cut.

URBN (+4.2% today, +9.8% week) — $76.07 → $85.00 (+11.7% upside) Valuation: Record revenue quarter with accelerating growth — likely trading at a discount to peers like Abercrombie given the recent drawdown despite similar fundamentals. Upside: “Bull of the Day” coverage + record results + RSI at 6.6 = textbook swing setup with clear upside to the 50-day MA. Risk: Retail sentiment shifts overnight on any consumer confidence miss; Iran headlines could trigger another broad discretionary selloff.

CDNA (+21.8% today, +25.5% week) — $36.52 → $42.00 (+15.0% upside) Valuation: At ~4x revenue for a diagnostics company expanding into oncology (a higher-multiple vertical), CDNA is reasonably valued vs. genomics/precision medicine peers. Upside: Naveris acquisition gives it a Medicare-covered oncology test with clear reimbursement pathway; the AI diagnostics narrative adds further re-rating potential. Risk: Integration risk on acquisitions; CEO sold shares in June (though scheduled); 21% single-day moves often see profit-taking within 48 hours.

Avoid

CNMD (+5.4%, RSI 71.5) — Already the most overbought name in today’s top 20. M&A rumors are binary — if no deal materializes, this retraces to $38-40 fast. The RSI at 71.5 while the rest of the list sits at oversold extremes tells you the easy money has been made.

MAAS (+14.2%) — No fresh catalyst today, just momentum continuation on an ADR that surged 84% in April on vague “AI positioning.” No earnings to anchor valuation, no specific product revenue disclosed. This is the kind of name that gaps down 20% on a single headline about China regulation or accounting questions.

RRR (+4.6%) — Zacks just added it to their Strong Sell list on July 10. Gaming/casino names face Iran-related consumer spending headwinds, and there’s no company-specific catalyst driving today’s move — pure sector sympathy with no conviction.

WSB Sentiment Check

MU — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — Memory stocks are getting crushed today (SK Hynix plunging, Sandisk plunging), and MU trades in lockstep with these names. WSB is likely bottom-fishing after the sector-wide selloff, which can work on a 1-2 week timeframe, but catching falling knives in semiconductors during an earnings-driven reset requires patience. Wait for stabilization before entering.

ASTS — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — AST SpaceMobile is a legitimate direct-to-cell satellite play with real commercial agreements, but it’s pre-revenue and valuation is entirely based on optionality. The SpaceX IPO falling back to its offering price shows the market is repricing space/satellite names lower. Trade carefully.

SNDK — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — Sandisk is literally in today’s headline as “plunging.” WSB calling it bullish while it’s in freefall suggests they’re trying to catch a knife. Memory/storage is in a cyclical downturn pocket right now with TSMC earnings disappointing. Let this settle before buying.

MSFT — WSB says: BULLISH (80% bullish) Claude says: AGREE — Microsoft is a quality compounder being tokenized in the DTCC pilot (institutional validation), and any Nasdaq weakness creates buying opportunities in names with AI monetization runway. Azure growth and Copilot adoption provide fundamental support.

TSM — WSB says: BULLISH (80% bullish) Claude says: DISAGREE SHORT-TERM — TSMC just sold off on earnings today. The long-term AI infrastructure thesis is intact, but buying on the day of an earnings miss/disappointment is premature. Let the dust settle for 2-3 sessions and look for support to form before entering.

Earnings Scorecard

CTAS — BEAT | Stock: +5.9% | Reported: Yesterday After Close Record FY26 results with Q4 revenue of $2.91B and net income of $511M. FY27 revenue guidance of $12.1-12.25B above consensus. The +5.9% reaction is JUSTIFIED but arguably insufficient given the quality of the beat and the extreme oversold starting point (RSI 14.9). This is a buy — the mean-reversion trade has weeks to run.

TSMC — MISS/DISAPPOINT | Stock: Down (per headlines) | Reported: Today Before Open TSMC selling off despite being the backbone of AI infrastructure suggests either guidance disappointed or margins compressed. Given WSB’s bullish stance, this is a “wait and see” — not a buy-the-dip yet until we see where support forms.